Characteristics of toxic epidermal necrolysis in patients undergoing long-term glucocorticoid therapy.
METHODS
The usefulness of steroid therapy in toxic epidermal necrolysis (TEN) remains controversial. Up to 5% of the TEN cases occur in patients who undergo long-term steroid therapy. We, thus, looked for the potential effect of long-term glucocorticosteroid therapy before the onset of TEN on altering the progression of the disease. The records of 179 patients were reviewed. The characteristics of the 13 patients who were undergoing long-term glucocorticosteroid therapy were compared with those of 166 other patients with TEN. The following parameters were studied: age, mortality, delay between the introduction of the suspect drug and the onset of TEN, length of hospital stay, body surface area involved, time elapsed between the first symptom of TEN and hospital admission, number of medications taken by the patients before the onset of TEN, lymphocyte count, granulocyte count, platelet count, glycemia, serum aspartate aminotransferase level, and total disease duration.


RESULTS
Patients who were undergoing long-term glucocorticosteroid therapy differed from other patients with TEN in the administration of more drugs, longer delay between the introduction of the suspect drug and the onset of TEN, and a longer time elapsed between the first symptom of TEN and hospital admission. We observed no differences for the other parameters that were studied.


CONCLUSIONS
Our study shows that long-term steroid therapy may delay the onset of TEN, but it does not halt its progression.
Guibal
F
F
Department of Dermatology, Hôpital Henri Mondor, Université Paris XII, Créteil, France.
Bastuji-Garin
S
S
Chosidow
O
O
Saiag
P
P
Revuz
J
J
Roujeau
J C
JC
D000293:Adolescent; D000328:Adult; D000367:Age Factors; D000368:Aged; D001219:Aspartate Aminotransferases / Q000097:blood; D001786:Blood Glucose / Q000032:analysis; D001830:Body Surface Area; D018450:Disease Progression; D005260:Female; D005938:Glucocorticoids / Q000008:administration & dosage / Q000627:therapeutic use*; D006801:Humans; D007902:Length of Stay; D007958:Leukocyte Count; D018655:Lymphocyte Count; D008297:Male; D008875:Middle Aged; D010343:Patient Admission; D010976:Platelet Count; D012189:Retrospective Studies; D013262:Stevens-Johnson Syndrome / Q000209:etiology* / Q000517:prevention & control
D001786:Blood Glucose; D005938:Glucocorticoids; D001219:Aspartate Aminotransferases